Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 1 to 12, 13, 17 and 18 as indicated.

Please cancel claims 14 to 16 and 19 to 25 without prejudice or disclaimer.

Listing of the Claims:

Claim 1 (currently amended): A compound of formula **(I)**:



(I)

wherein

$\mathbf{M^1}$ is $-CH_2-$ or $-NR^{21}-$;

$\mathbf{M^2}$ is $-CR^{22}R^{23}-$ or $-NR^{24}-$; provided that if M^1 is $-NR^{21}-$, M^2 is $-CR^{22}R^{23}-$;

one ~~One of~~ $\mathbf{R^1}$ and $\mathbf{R^2}$ are ~~are~~ selected from hydrogen, C_{1-6}alkyl or C_{2-6}alkenyl and the other is selected from C_{1-6}alkyl or C_{2-6}alkenyl;

$\mathbf{R^3}$ is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkyl$S(O)_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl and *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl;

v is 0-5;

one of $\mathbf{R^5}$ and $\mathbf{R^6}$ is a group of formula **(IA)**:



(IA)

R^{4} and **R**^{7} and the other of **R**^{5} and **R**^{6} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N*,*N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N*,*N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl and *N*,*N*-(C_{1-4}alkyl)$_2$sulphamoyl; wherein R^{4} and R^{7} and the other of R^{5} and R^{6} may be optionally substituted on carbon by one or more R^{25};

Z is -O-, -N(R^{a})-, -S(O)$_b$- or -CH(R^{a})-; wherein R^{a} is hydrogen or C_{1-6}alkyl and b is 0-2;

R^{8} is hydrogen, C_{1-4}alkyl, carbocyclyl or heterocyclyl; wherein R^{8} may be optionally substituted on carbon by one or more substituents selected from R^{26}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{27};

R^{9} is hydrogen or C_{1-4}alkyl;

R^{10} and **R**^{11} are independently selected from hydrogen, C_{1-4}alkyl, carbocyclyl or heterocyclyl; or R^{10} and R^{11} together form C_{2-6}alkylene; wherein R^{10} and R^{11} or R^{10} and R^{11} together may be independently optionally substituted on carbon by one or more substituents selected from R^{28}; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by one or more R^{29};

R^{12} is hydrogen, C_{1-4}alkyl, carbocyclyl or heterocyclyl; wherein R^{12} may be optionally substituted on carbon by one or more substituents selected from R^{30}; and wherein if said heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by one or more R^{31};

R^{13} is hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10}alkyl, C_{2-10}alkenyl, C_{2-10}alkynyl, C_{1-10}alkoxy,

C_{1-10}alkoxycarbonyl, C_{1-10}alkanoyl, C_{1-10}alkanoyloxy, *N*-(C_{1-10}alkyl)amino, *N,N*-(C_{1-10}alkyl)$_2$amino, *N,N,N*-(C_{1-10}alkyl)$_3$ammonio, C_{1-10}alkanoylamino, *N*-(C_{1-10}alkyl)carbamoyl, *N,N*-(C_{1-10}alkyl)$_2$carbamoyl, C_{1-10}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-10}alkyl)sulphamoyl, *N,N*-(C_{1-10}alkyl)$_2$sulphamoyl, *N*-(C_{1-10}alkyl)sulphamoylamino, *N,N*-(C_{1-10}alkyl)$_2$sulphamoylamino, C_{1-10}alkoxycarbonylamino, carbocyclyl, carbocyclylC_{1-10}alkyl, heterocyclic group, heterocyclylC_{1-10}alkyl, carbocyclyl-(C_{1-10}alkylene)$_e$-R^{32}-(C_{1-10}alkylene)$_f$- or heterocyclyl-(C_{1-10}alkylene)$_g$-R^{33}-(C_{1-10}alkylene)$_h$-; wherein R^{13} may be optionally substituted on carbon by one or more substituents selected from R^{36}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{37}; or R^{13} is a group of formula **(IB)**:



(IB)

wherein:

X is –N(R^{38})-, -N(R^{38})C(O)-, -O-, and -S(O)$_a$-; wherein a is 0-2 and R^{38} is hydrogen or C_{1-4}alkyl;

R^{14} is hydrogen or C_{1-4}alkyl;

R^{15} and **R^{16}** are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, carbocyclyl or heterocyclic group; wherein R^{15} and R^{16} may be independently optionally substituted on carbon by one or more substituents selected from R^{41}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{42};

$\mathbf{R^{17}}$ is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, $C_{1\text{-}10}$alkyl, $C_{2\text{-}10}$alkenyl, $C_{2\text{-}10}$alkynyl, $C_{1\text{-}10}$alkoxy, $C_{1\text{-}10}$alkanoyl, $C_{1\text{-}10}$alkanoyloxy, *N*-($C_{1\text{-}10}$alkyl)amino, *N,N*-($C_{1\text{-}10}$alkyl)$_2$amino, $C_{1\text{-}10}$alkanoylamino, *N*-($C_{1\text{-}10}$alkyl)carbamoyl, $C_{1\text{-}10}$alkoxycarbonyl, *N,N*-($C_{1\text{-}10}$alkyl)$_2$carbamoyl, $C_{1\text{-}10}$alkylS(O)$_a$ wherein a is 0 to 2, *N*-($C_{1\text{-}10}$alkyl)sulphamoyl, *N,N*-($C_{1\text{-}10}$alkyl)$_2$sulphamoyl, *N*-($C_{1\text{-}10}$alkyl)sulphamoylamino, *N,N*-($C_{1\text{-}10}$alkyl)$_2$sulphamoylamino, carbocyclyl, carbocyclyl$C_{1\text{-}10}$alkyl, heterocyclic group, heterocyclyl$C_{1\text{-}10}$alkyl, carbocyclyl-($C_{1\text{-}10}$alkylene)$_e$-R^{43}-($C_{1\text{-}10}$alkylene)$_f$- or heterocyclyl-($C_{1\text{-}10}$alkylene)$_g$-R^{44}-($C_{1\text{-}10}$alkylene)$_h$-; wherein R^{17} may be optionally substituted on carbon by one or more substituents selected from R^{47}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{48}; or R^{17} is a group of formula **(IC)**:



(IC)

wherein:

$\mathbf{R^{18}}$ is selected from hydrogen or $C_{1\text{-}4}$alkyl;

$\mathbf{R^{19}}$ is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkenyl, $C_{2\text{-}6}$alkynyl, $C_{1\text{-}6}$alkoxy, $C_{1\text{-}6}$alkanoyl, $C_{1\text{-}6}$alkanoyloxy, *N*-($C_{1\text{-}6}$alkyl)amino, *N,N*-($C_{1\text{-}6}$alkyl)$_2$amino, $C_{1\text{-}6}$alkanoylamino, *N*-($C_{1\text{-}6}$alkyl)carbamoyl, *N,N*-($C_{1\text{-}6}$alkyl)$_2$carbamoyl, $C_{1\text{-}6}$alkylS(O)$_a$ wherein a is 0 to 2, $C_{1\text{-}6}$alkoxycarbonyl, *N*-($C_{1\text{-}6}$alkyl)sulphamoyl, *N,N*-($C_{1\text{-}6}$alkyl)$_2$sulphamoyl, carbocyclyl or heterocyclic group; where R^{19} may be independently optionally substituted on carbon by one or more substituents selected from R^{51}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{52};

$\mathbf{R^{20}}$ is selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, $C_{1\text{-}10}$alkyl, $C_{2\text{-}10}$alkenyl, $C_{2\text{-}10}$alkynyl, $C_{1\text{-}10}$alkoxy,

C_{1-10}alkoxycarbonyl, C_{1-10}alkanoyl, C_{1-10}alkanoyloxy, *N*-(C_{1-10}alkyl)amino, *N,N*-(C_{1-10}alkyl)$_2$amino, *N,N,N*-(C_{1-10}alkyl)$_3$ammonio, C_{1-10}alkanoylamino, *N*-(C_{1-10}alkyl)carbamoyl, *N,N*-(C_{1-10}alkyl)$_2$carbamoyl, C_{1-10}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-10}alkyl)sulphamoyl, *N,N*-(C_{1-10}alkyl)$_2$sulphamoyl, *N*-(C_{1-10}alkyl)sulphamoylamino, *N,N*-(C_{1-10}alkyl)$_2$sulphamoylamino, C_{1-10}alkoxycarbonylamino, carbocyclyl, carbocyclylC_{1-10}alkyl, heterocyclic group, heterocyclylC_{1-10}alkyl, carbocyclyl-(C_{1-10}alkylene)$_e$-R^{53}-(C_{1-10}alkylene)$_f$- or heterocyclyl-(C_{1-10}alkylene)$_g$-R^{54}-(C_{1-10}alkylene)$_h$-; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{57}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{58};

p is 1-3; wherein the values of R^{15} may be the same or different;

q is 0-1;

r is 0-3; wherein the values of R^{16} may be the same or different;

m is 0-2; wherein the values of R^{12} may be the same or different;

n is 1-2; wherein the values of R^{8} may be the same or different;

z is 0-3; wherein the values of R^{19} may be the same or different;

$\mathbf{R^{21}}$ is selected from hydrogen or C_{1-6}alkyl;

$\mathbf{R^{22}}$ and $\mathbf{R^{23}}$ are independently selected from hydrogen, hydroxy, amino, mercapto, C_{1-6}alkyl, C_{1-6}alkoxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2;

$\mathbf{R^{24}}$ is selected from hydrogen, hydroxy, C_{1-6}alkyl, C_{1-4}alkoxy and C_{1-6}alkanoyloxy;

$\mathbf{R^{25}}$ is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, C_{1-4}alkanoylamino, *N*-(C_{1-4}alkyl)carbamoyl, *N,N*-(C_{1-4}alkyl)$_2$carbamoyl, C_{1-4}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-4}alkoxycarbonyl, *N*-(C_{1-4}alkyl)sulphamoyl and *N,N*-(C_{1-4}alkyl)$_2$sulphamoyl; wherein R^{25}, may be independently optionally substituted on carbon by one or more R^{67};

$\mathbf{R^{26}}$, $\mathbf{R^{28}}$, $\mathbf{R^{30}}$, $\mathbf{R^{36}}$, $\mathbf{R^{41}}$, $\mathbf{R^{47}}$, $\mathbf{R^{51}}$ and $\mathbf{R^{57}}$ are independently selected from halo, nitro, cyano, hydroxy, amino, carbamoyl, mercapto, sulphamoyl, hydroxyaminocarbonyl, C_{1-10}alkyl, C_{2-10}alkenyl, C_{2-10}alkynyl, C_{1-10}alkoxy, C_{1-10}alkanoyl, C_{1-10}alkanoyloxy, C_{1-10}alkoxycarbonyl,

N-(C_{1-10}alkyl)amino, *N,N*-(C_{1-10}alkyl)$_2$amino, *N,N,N*-(C_{1-10}alkyl)$_3$ammonio, C_{1-10}alkanoylamino, *N*-(C_{1-10}alkyl)carbamoyl, *N,N*-(C_{1-10}alkyl)$_2$carbamoyl, C_{1-10}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-10}alkyl)sulphamoyl, *N,N*-(C_{1-10}alkyl)$_2$sulphamoyl, *N*-(C_{1-10}alkyl)sulphamoylamino, *N,N*-(C_{1-10}alkyl)$_2$sulphamoylamino, C_{1-10}alkoxycarbonylamino, carbocyclyl, carbocyclylC_{1-10}alkyl, heterocyclic group, heterocyclylC_{1-10}alkyl, carbocyclyl-(C_{1-10}alkylene)$_e$-R^{59}-(C_{1-10}alkylene)$_f$- or heterocyclyl-(C_{1-10}alkylene)$_g$-R^{60}-(C_{1-10}alkylene)$_h$-; wherein R^{26}, R^{28}, R^{30}, R^{36}, R^{41}, R^{47}, R^{51} and R^{57} may be independently optionally substituted on carbon by one or more R^{63}; and wherein if said heterocyclyl contains an -NH- group, that nitrogen may be optionally substituted by a group selected from R^{64};

R^{27}, **R^{29}**, **R^{31}**, **R^{37}**, **R^{42}**, **R^{48}**, **R^{52}**, **R^{58}** and **R^{64}** are independently selected from C_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, sulphamoyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, benzyl, phenethyl, benzoyl, phenylsulphonyl and phenyl;

R^{32}, **R^{33}**, **R^{43}**, **R^{44}**, **R^{53}**, **R^{54}**, **R^{59}** and **R^{60}**are independently selected from -O-, -NR^{65}-, -S(O)$_x$-, -NR^{65}C(O)NR^{66}-, -NR^{65}C(S)NR^{66}-, -OC(O)N=C-, -NR^{65}C(O)- or -C(O)NR^{65}-; wherein R^{65} and R^{66} are independently selected from hydrogen or C_{1-6}alkyl, and x is 0-2;

R^{63} and **R^{67}** re independently selected from halo, hydroxy, cyano, carbamoyl, ureido, amino, nitro, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl, methoxy, ethoxy, vinyl, allyl, ethynyl, methoxycarbonyl, formyl, acetyl, formamido, acetylamino, acetoxy, methylamino, dimethylamino, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, methylthio, methylsulphinyl, mesyl, *N*-methylsulphamoyl and *N,N*-dimethylsulphamoyl; and

e, **f**, **g** and **h** are independently selected from 0-2;

or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 2 (currently amended): A compound of formula **(I)** according to claim 1 wherein M^1 is -CH_2- and M^2 is -$CR^{22}R^{23}$-; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 3 (currently amended): A compound of formula **(I)** according to claim 1 wherein M^1 is $-CH_2-$ and M^2 is $-NR^{24}-$; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 4 (currently amended): A compound of formula **(I)** according to claim 1 ~~or 2~~ wherein R^{22} and R^{23} are independently selected from hydrogen and hydroxy; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 5 (currently amended): A compound of formula **(I)** according to claim 1 ~~or 3~~ wherein R^{24} is hydrogen; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 6 (currently amended): A compound of formula **(I)** according to claim 1 ~~any one of claims 1-5~~ wherein R^1 and R^2 are C_{1-4}alkyl; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 7 (currently amended): A compound of formula **(I)** according to claim 1 ~~any one of claims 1-6~~ wherein v is 0; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 8 (currently amended): A compound of formula **(I)** according to claim 1 ~~any one of claims 1-7~~ wherein R^4 and R^7 are hydrogen; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 9 (currently amended): A compound of formula **(I)** according to claim 1 ~~any one of claims 1-8~~ wherein the R^5 or R^6 not selected from a group of formula **(IA)** is hydrogen or methylthio; or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 10 (currently amended): A compound of formula **(I)** according to claim 1 ~~any one of claims 1-9~~ wherein one of R^5 and R^6 is a group of formula **(IA)** ~~(as depicted above);~~ wherein:

Z is -O- or -$S(O)_b$-; wherein b is 0;

$\mathbf{R^8}$ is hydrogen;

$\mathbf{R^9}$ is hydrogen;

$\mathbf{R^{10}}$ and $\mathbf{R^{11}}$ are independently selected from hydrogen or carbocyclyl; wherein R^{10} and R^{11} may be independently optionally substituted on carbon by one or more substituents selected from R^{28};

$\mathbf{R^{13}}$ is a group of formula **(IB)** (as depicted above);

$\mathbf{R^{14}}$ is hydrogen;

$\mathbf{R^{15}}$ is hydrogen;

$\mathbf{R^{17}}$ is C_{1-10}alkyl; wherein R^{17} may be optionally substituted on carbon by one or more substituents selected from R^{47}; or R^{17} is a group of formula **(IC)** (as depicted above) wherein:

$\mathbf{R^{18}}$ is selected from hydrogen;

$\mathbf{R^{19}}$ is selected from hydrogen;

$\mathbf{R^{20}}$ is C_{1-10}alkyl; wherein R^{20} may be independently optionally substituted on carbon by one or more R^{57};

p is 1;

q is 0;

r is 0;

m is 0;

n is 1;

z is 1; and

$\mathbf{R^{28}}$, $\mathbf{R^{47}}$ and $\mathbf{R^{57}}$ are independently selected from halo and hydroxy

or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 11 (currently amended): A compound of formula **(I)** wherein:

$\mathbf{M^1}$ is -CH_2-;

$\mathbf{M^2}$ is $-CR^{22}R^{23}-$ and $-NR^{24}-$;

$\mathbf{R^{22}}$ and $\mathbf{R^{23}}$ are independently selected from hydrogen and hydroxy;

one ~~One~~ of $\mathbf{R^1}$ and $\mathbf{R^2}$ is ethyl and the other is butyl;

v is 0;

$\mathbf{R^4}$ and $\mathbf{R^7}$ are hydrogen;

one ~~One~~ of $\mathbf{R^5}$ or $\mathbf{R^6}$ is selected from a group of formula **(IA)** (as depicted above) and the other is hydrogen or methylthio;

Z is -O- or $-S(O)_b-$; wherein b is 0;

$\mathbf{R^8}$ is hydrogen;

$\mathbf{R^9}$ is hydrogen;

$\mathbf{R^{10}}$ and $\mathbf{R^{11}}$ are independently selected from hydrogen, 2-fluorophenyl or carbocyclyl;

$\mathbf{R^{13}}$ is a group of formula **(IB)** (as depicted above);

$\mathbf{R^{14}}$ is hydrogen;

$\mathbf{R^{15}}$ is hydrogen;

$\mathbf{R^{17}}$ is pentyl substituted by 5 hydroxy; or R^{17} is a group of formula **(IC)** (as depicted above) wherein:

$\mathbf{R^{18}}$ is selected from hydrogen;

$\mathbf{R^{19}}$ is selected from hydrogen;

$\mathbf{R^{20}}$ is pentyl substituted by 5 hydroxy;

p is 1;

q is 0;

r is 0;

m is 0;

n is 1; and

z is 1;

or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 12 (currently amended): A compound of formula **(I)** according to claim 1 selected from:

(+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

(+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine;

1,1-dioxo-3-ethyl-3-butyl-4-hydroxy-5-phenyl-7-(*N*-{α-[*N*'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-2-fluorobenzyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine; or

1,1-dioxo-3-butyl-3-ethyl-4-hydroxy-5-phenyl-7-(*N*-{1-[*N*'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-1-(cyclohexyl)methyl}carbamoylmethylthio)-2,3,4,5-tetrahydrobenzothiepine;

or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof.

Claim 13 (currently amended and withdrawn): A process for preparing a compound of formula **(I)** or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof, as claimed in claim 1 ~~anyone of claims 1-12~~, which process (wherein variable groups are, unless otherwise specified, as defined in claim 1) comprises of:

Process 1): for compounds of formula **(I)** wherein Z is -O-,-NR^a or -S-; reacting a compound of formula **(IIa)** or **(IIb)**:



(IIa)



(IIb)

with a compound of formula **(III)**:



(III)

wherein L is a displaceable group;

Process 2): reacting an acid of formula **(IVa)** or **(IVb)**:



(IVa)



(IVb)

or an activated derivative thereof; with an amine of formula **(V)**:



(V);

Process 3): for compounds of formula **(I)** wherein R^{13} is a group of formula **(IB)**; reacting an acid of formula **(VIa)**:



(VIa)

or **(VIb)**:



(VIb)

with an amine of formula:



(VI)

Process 4): for compounds of formula **(I)** wherein R^{13} is a group of formula **(IB)** and R^{17} is a group of formula **(IC)**; reacting an acid of formula **(VIIIa)**:



(VIIIa)

or **(VIIIb)**



(VIIIb)

or an activated derivative thereof; with an amine of formula **(IX)**:

(IX)

Process 5) for compounds of formula **(I)** wherein one of R^5 and R^6 are independently selected from C_{1-6}alkylthio optionally substituted on carbon by one or more R^{25}; reacting a compound of formula **(Xa)** or **(Xb)**:



(Xa)



(Xb)

wherein L is a displaceable group; with a thiol of formula **(XI)**:

R^m-H

(XI)

wherein R^m is C_{1-6}alkylthio optionally substituted on carbon by one or more R^{25};

and optionally ~~thereafter if necessary or desirable~~:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug.

Claims 14 to 16 (cancelled).

Claim 17 (currently amended and withdrawn): A method for producing an IBAT inhibitory effect in a warm-blooded animal~~, such as man,~~ in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)**, or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof, as claimed in claim 1 or claim 11 ~~any one of claims 1 to 12~~.

Claim 18 (currently amended): A pharmaceutical composition which comprises a compound of formula **(I)**, or a pharmaceutically acceptable salt~~, solvate, solvate of such a salt~~ or a prodrug thereof, as claimed in claim 1 or claim 11 ~~any one of claims 1 to 12~~, in association with a

pharmaceutically-acceptable diluent or carrier.

Claims 19 to 25 (cancelled).